Doctors use trial-based evidence and years of experience to assess risks of treatment and relapse. But patients make choices based on their own experiences and priorities. How can doctors best explore treatment options with patients? [more]
The use of nucleic acid therapies to block RNA function was first described in 1978. The latest generation of these compounds, LNA antagonists, is now overcoming the main obstacle to the success of its predecessors, [more]
The biology of a cancer is a key factor determining prognosis and prediction of response. So should we still be characterising it by the size of the tumour and spread of the disease? In a [more]
There are smokers in Russia alive today thanks to David Zaridze and the lead he took in halving tar levels 20 years ago. He has a long history in cancer prevention, but believes the biggest [more]
Use of at least two standard aspirin weekly, for 10 years or more, reduces colon cancer risk in women. Subject to certain caveats, aspirin should be considered for colon cancer prophylaxis. Download full article
A recent analysis of prognostic factors may help identify which follicular and mantle cell lymphoma patients should be excluded from trials of single-agent rituximab therapy. Download full article
Selected press reports compiled by the ESO Cancer Media Centre Download full article
Multidisciplinary teams provide the best quality cancer care, as specialists come together to discuss diagnoses and plan treatments. They raise standards, improve patient experiences and save lives. Sadly, most of Europe’s cancer patients never have [more]
More and more cancer patients are using the Internet to find out about their disease and treatment, to seek support from online patient communities and to communicate with their professional carers and loved ones. However, [more]
Our new-found ability to profile the gene expression of a tumour is transforming the way we characterise cancers and decide on treatment. Laura van ‘t Veer was there from the start, and she’s now splitting [more]
Clinical research activity may be plummeting in the rest of Europe, but in France they’re determined to substantially increase the numbers of hospitals and patients involved in clinical trials starting with a strategic trial [more]
Michael Sporn believes the best bet for controlling cancer is to pick up the warning signs and nip it in the bud. A pot of gold awaits any drugs company that can come up with [more]
Estimates of the death toll from the nuclear reactor disaster at Chernobyl vary widely depending on who you listen to. But with leukaemia rates still rising, and a recent marked increase in solid tumours among [more]